Dr Michael Bowen is co-founder and Head of Translational Science for Kinoxis Therapeutics. Photo: Stefanie Zingsheim
University of Sydney spinout Kinoxis Therapeutics awarded US National Institutes of Health HEAL Initiative grant of up to $6.8m. Out of 375 grants this is the only one awarded outside North America. Kinoxis Therapeutics has been awarded a grant for a potential of up to $US4.6 million ($6.8 million) under the USA National Institutes of Health Helping to End Addiction Long-Term, or the NIH HEAL Initiative. The primary target of Kinoxis is the brain oxytocin system, which receives considerable interest for its role in the regulation of social behaviour and inhibitory effects on addictive behaviours. Out of 375 funding grants awarded under the HEAL Initiative, Kinoxis Therapeutics' grant is the only one received outside North America. The funding from the NIH HEAL Initiative is to further develop the company's lead compound, KNX100, for the treatment of opioid withdrawal. KNX100 is a drug that was discovered by researchers at the University of Sydney that is being commercialised by Kinoxis Therapeutics.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
